Pemafibrate

DB15212InvestigationalSmall molecule

Pemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)).

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor alpha
Curator reviewed
Formula / weight: C₂₈H₃₀N₂O₆ · 490.556 g/mol (avg)
Code names: K-877

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyZHKNLJLMDFQVHJ-RUZDIDTESA-NSMILESCC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C2=NC3=C(O2)C=CC=C3)=CC=C1)C(O)=O

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

81Drug interactionsStructured to mechanism, not free text

20Clinical trialsPhase, status and sponsor resolved per trial

1Marketed productAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 9 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pemafibrate, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.